Bioqual, Inc.
BIOQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$29.52M
Close$
$10.20
69.1% downside
Current Fair Value
69.1% downsideOvervalued by 69.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $29.52 Million |
|---|---|
| Enterprise Value | $51.54 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.66 |
| Beta | -0.09 |
| Outstanding Shares | 894,416 |
Return
| Return on Equity | -12.86% |
|---|---|
| Return on Assets | -6.09% |
| Return on Invested Capital | -6.56% |
Valuation & Multiples
| P/E Ratio | -7.08 |
|---|---|
| PEG | -0.23 |
| Price to Sales | 0.75 |
| Price to Book Ratio | 0.92 |
| Enterprise Value to Revenue | 1.29 |
| Enterprise Value to EBIT | -12.65 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0.64 |
| Debt to Equity | 1.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 21, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bioqual, Inc.
278 employees
CEO: Hanne Andersen-Elyard Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise ...